1830 related articles for article (PubMed ID: 17766613)
21. Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers.
Palomaki GE; Neveux LM; Knight GJ; Haddow JE
Prenat Diagn; 2003 Mar; 23(3):243-7. PubMed ID: 12627428
[TBL] [Abstract][Full Text] [Related]
22. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.
Aitken DA; Wallace EM; Crossley JA; Swanston IA; van Pareren Y; van Maarle M; Groome NP; Macri JN; Connor JM
N Engl J Med; 1996 May; 334(19):1231-6. PubMed ID: 8606718
[TBL] [Abstract][Full Text] [Related]
23. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years.
Biggio JR; Morris TC; Owen J; Stringer JS
Am J Obstet Gynecol; 2004 Mar; 190(3):721-9. PubMed ID: 15042005
[TBL] [Abstract][Full Text] [Related]
24. First- and second-trimester evaluation of risk for Down syndrome.
Ball RH; Caughey AB; Malone FD; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Emig D; D'Alton ME;
Obstet Gynecol; 2007 Jul; 110(1):10-7. PubMed ID: 17601890
[TBL] [Abstract][Full Text] [Related]
25. Triploidy identified through second-trimester serum screening.
Huang T; Alberman E; Wald N; Summers AM
Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
[TBL] [Abstract][Full Text] [Related]
26. Advanced first trimester screening (AFS): an improved test strategy for the individual risk assessment of fetal aneuploidies and malformations.
Schmidt P; Rom J; Maul H; Vaske B; Hillemanns P; Scharf A
Arch Gynecol Obstet; 2007 Aug; 276(2):159-66. PubMed ID: 17342500
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
[TBL] [Abstract][Full Text] [Related]
28. Repeated measurement of pregnancy-associated plasma protein-A (PAPP-A) in Down syndrome screening: a validation study.
Palomaki GE; Wright DE; Summers AM; Neveux LM; Meier C; O'donnell A; Huang T; Knight GJ; Haddow JE
Prenat Diagn; 2006 Aug; 26(8):730-9. PubMed ID: 16810709
[TBL] [Abstract][Full Text] [Related]
29. Integrated first- and second-trimester Down syndrome screening test among unaffected IVF pregnancies.
Maymon R; Shulman A
Prenat Diagn; 2004 Feb; 24(2):125-9. PubMed ID: 14974121
[TBL] [Abstract][Full Text] [Related]
30. Second-trimester maternal serum quadruple test for Down syndrome screening: a Taiwanese population-based study.
Shaw SW; Lin SY; Lin CH; Su YN; Cheng PJ; Lee CN; Chen CP
Taiwan J Obstet Gynecol; 2010 Mar; 49(1):30-4. PubMed ID: 20466289
[TBL] [Abstract][Full Text] [Related]
31. Screening for fetal aneuploidies at 11 to 13 weeks.
Nicolaides KH
Prenat Diagn; 2011 Jan; 31(1):7-15. PubMed ID: 21210475
[TBL] [Abstract][Full Text] [Related]
32. Maternal weight and ethnic adjustment within a first-trimester Down syndrome and trisomy 18 screening program.
Krantz DA; Hallahan TW; Macri VJ; Macri JN
Prenat Diagn; 2005 Aug; 25(8):635-40. PubMed ID: 16049986
[TBL] [Abstract][Full Text] [Related]
33. Effect on Down syndrome screening performance of adjusting for marker levels in a previous pregnancy.
Wald NJ; Barnes IM; Birger R; Huttly W
Prenat Diagn; 2006 Jun; 26(6):539-44. PubMed ID: 16634123
[TBL] [Abstract][Full Text] [Related]
34. Clinical first-trimester routine screening for Down syndrome in singleton pregnancies in northern Finland.
Valinen Y; Rapakko K; Kokkonen H; Laitinen P; Tekay A; Ahola T; Ryynanen M
Am J Obstet Gynecol; 2007 Mar; 196(3):278.e1-5. PubMed ID: 17346554
[TBL] [Abstract][Full Text] [Related]
35. Impact of smoking on maternal serum markers and prenatal screening in the first and second trimesters.
Zhang J; Lambert-Messerlian G; Palomaki GE; Canick JA
Prenat Diagn; 2011 Jun; 31(6):583-8. PubMed ID: 21480302
[TBL] [Abstract][Full Text] [Related]
36. First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free beta human chorionic gonadotophin, pregnancy-associated plasma protein-A and nuchal translucency.
Bestwick JP; Huttly WJ; Wald NJ
J Med Screen; 2008; 15(4):204-6. PubMed ID: 19106261
[TBL] [Abstract][Full Text] [Related]
37. [The prenatal detection of trisomy 13, 18, and 21: comparison of the advanced first trimester screening (AFS) with the first trimester screening according to Nicolaides].
Hörmansdörfer C; Schmidt P; Hillemanns P; Scharf A
Z Geburtshilfe Neonatol; 2007 Dec; 211(6):243-9. PubMed ID: 18176905
[TBL] [Abstract][Full Text] [Related]
38. SURUSS in perspective.
Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
[TBL] [Abstract][Full Text] [Related]
39. Contingent screening for Down syndrome--results from the FaSTER trial.
Cuckle HS; Malone FD; Wright D; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Ferreira JC; Dugoff L; Craigo SD; Timor IE; Carr SR; Wolfe HM; D'Alton ME
Prenat Diagn; 2008 Feb; 28(2):89-94. PubMed ID: 18236423
[TBL] [Abstract][Full Text] [Related]
40. Is there a nuchal translucency millimeter measurement above which there is no added benefit from first trimester serum screening?
Comstock CH; Malone FD; Ball RH; Nyberg DA; Saade GR; Berkowitz RL; Ferreira J; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Bianchi DW; D'Alton ME;
Am J Obstet Gynecol; 2006 Sep; 195(3):843-7. PubMed ID: 16949423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
